Down syndrome and dementia: advances in the field

Purpose of review People with Down syndrome represent the world's largest population with a genetic risk for Alzheimer's disease. This review will provide a short summary of what is known and will include recent findings from the field. Recent findings There has been an increasing focus on biomarker research in this population, with a number of studies presenting findings on promising new markers – Neurofilament Light (NfL) appears to be one such promising marker that has emerged. Imaging studies have increased our knowledge on the progression of Alzheimer's disease in this population. Summary The inclusion of people with Down syndrome in dementia research is vital from a scientific and an equity perspective. Recent advances in the field can have further impact with multisite, cross country collaborative efforts. For this to happen, instruments need to be validated across language and cultures.
Source: Current Opinion in Psychiatry - Category: Psychiatry Tags: GERIATRIC PSYCHIATRY Source Type: research

Related Links:

Cortical laminar distribution of β-amyloid deposits in five neurodegenerative disorders. Folia Neuropathol. 2020;58(1):1-9 Authors: A Armstrong R Abstract Alzheimer's disease neuropathologic change (ADNC) in the form of β-amyloid (Aβ) deposits occurs not only in Alzheimer's disease (AD) and Down's syndrome (DS) but also as a 'co-pathology' in several disorders including dementia with Lewy bodies (DLB), corticobasal degeneration (CBD), and chronic traumatic encephalopathy (CTE). To determine whether cortical laminar degeneration, as measured by Aβ deposition, is similar in different...
Source: Folia Neuropathologica - Category: Pathology Authors: Tags: Folia Neuropathol Source Type: research
ConclusionsFurther investigations are necessary to better evaluate the potential cognitive-enhancing role of intranasal insulin in the Down syndrome IDNCT02432716.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
Abstract Individuals with Down syndrome (DS) develop Alzheimer's disease (AD)-related neuropathology, characterized by amyloid plaques with amyloid β (Aβ) and neurofibrillary tangles with tau accumulation. Peripheral inflammation and the innate immune response are elevated in DS. Triggering receptor expressed in myeloid cells 2 (TREM2) genetic variants are risk factors for AD and other neurodegenerative diseases. Soluble TREM2 (sTREM2), a soluble cleavage product of TREM2, is elevated in AD cerebrospinal fluid and positively correlates with cognitive decline. There is relatively little information about ...
Source: Journal of Immunology - Category: Allergy & Immunology Authors: Tags: J Immunol Source Type: research
Abstract Alzheimer's disease (AD) is the most prevalent type of dementia. Down syndrome (DS) is the leading genetic risk factor for Early-Onset AD, prematurely presenting the classic pathological features of the brain with AD. Augmented gene dosage, including the APP gene, could partially cause this predisposition. Recent works have revealed that alterations in chromosome location due to the extra Chromosome 21, as well as epigenetic modifications, could promote changes in gene expression other than those from Chromosome 21. As a result, similar pathological features and cellular dysfunctions in DS and AD, includi...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
ConclusionsThe modified questionnaire and interview instruments capture a range of impairment in DS adults, including subthreshold symptomatology, and the instruments provide complementary information relevant to the ascertainment of dementia in DS. Decline was seen across all cognitive domains and was generally positively related to age and negatively related to IQ. Most importantly, adjusting instrument scores for chronic, premorbid impairment drastically shifted the distribution toward lower (no impairment) scores.
Source: Journal of Neurodevelopmental Disorders - Category: Neurology Source Type: research
Conditions:   Down Syndrome;   Alzheimer Disease;   Dementia Intervention:   Sponsors:   University of Southern California;   National Institute on Aging (NIA);   Alzheimer's Clinical Trial Consortium;   Alzheimer's Therapeutic Research Institute Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Title: Down Syndrome Carries Raised Risk of Dementia by 55Category: Health NewsCreated: 11/4/2019 12:00:00 AMLast Editorial Review: 11/5/2019 12:00:00 AM
Source: MedicineNet Alzheimer - Category: Geriatrics Source Type: news
MONDAY, Nov. 4, 2019 -- More than half of individuals with Down syndrome aged 55 years or older have dementia claims and 32.7 percent have Alzheimer disease (AD) claims, according to a research letter published online Oct. 28 in JAMA Neurology. Eric...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Alzheimer's | Brain | Dementia | Down's Syndrome | Genetics | Geriatrics | Neurology | Neuroscience | Psychiatry | Study